Zytiga® (Abiraterone Acetate)

DRUG2 trials

Sponsors

Sun Pharmaceutical Industries Limited, Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Conditions

Prostate CancerProstatic Neoplasms, Castration-Resistant

Phase 2

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT02737332

Sun Pharmaceutical Industries LimitedProstate Cancer

Start: 2016-03-21End: 2017-02-27Updated: 2021-11-22

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

RecruitingNCT07717268

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicProstatic Neoplasms, Castration-Resistant

Start: 2024-05-16End: 2030-05-16Target: 51Updated: 2026-07-21

Related Papers

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.

2025-03-014 citations

Pharmacokinetic (PK) subgroup results from the phase 2 pharmacodynamic and bioequivalence study of abiraterone acetate fine particle formulation (AAFP) in patients with metastatic castration-resistant prostate cancer (mCRPC): The STAAR study.

Journal of Clinical Oncology2018-02-20

Absorption of a novel formulation of abiraterone acetate (AA) fine particle (AAFP) under fed and fasted conditions.

Journal of Clinical Oncology2017-02-202 citations

Single-dose, four-way crossover, open-label, relative bioavailability (BA) studies of a novel formulation of abiraterone acetate (AA) versus the reference formulation under fasted conditions in healthy male subjects.

Journal of Clinical Oncology2017-02-20